08:51 AM EDT, 05/21/2024 (MT Newswires) -- Eli Lilly and Company ( LLY ) said Tuesday that a phase 3 study of patients with Crohn's disease treated with mirikizumab achieved statistically significant and clinically meaningful improvements across multiple clinical and endoscopic endpoints at one year compared to placebo.

The company said that after one year, clinical remission and endoscopic response were achieved by 54.1% and 48.4% of patients on mirikizumab, respectively.

Price: 786.33, Change: +3.15, Percent Change: +0.40